TherapeuticsMD Announces Pricing of $125 Million Common Stock Offering

BOCA RATON, Fla.–(BUSINESS WIRE)–TherapeuticsMD, Inc. (NYSE MKT: TXMD) today announced the pricing of an
underwritten public offering of $125 million of shares of its common
stock, offered at a price of $8.25 per share. The gross proceeds to
TherapeuticsMD from this offering are expected to be approximately $125
million, before deducting underwriting discounts, commissions and other
offering expenses payable by TherapeuticsMD. In addition, TherapeuticsMD
has granted the underwriters an option for a period of 30 days to
purchase, at the public offering price less the underwriting discount,
up to an additional 15% of the shares of common stock. All of the shares
in the offering are to be sold by TherapeuticsMD. The offering is
expected to close on or about January 12, 2016, subject to the
satisfaction of customary closing conditions.

Goldman, Sachs & Co. and Cowen and Company are acting as joint
bookrunning managers for the offering. Stifel and Guggenheim Securities
are acting as joint lead managers for the offering.

TherapeuticsMD intends to use a majority of the proceeds of the offering
to fund commercialization activities for TX-004HR, its applicator-free
vaginal estradiol softgel drug candidate, for other research, clinical
trials, clinical formulation and development and for working capital and
general corporate purposes.

TherapeuticsMD has filed a shelf registration statement on Form S-3,
including a prospectus supplement and accompanying prospectus, with the
Securities and Exchange Commission (the “SEC”), relating to the public
offering of the shares of common stock described above. Before buying
any shares of TherapeuticsMD’s common stock in the offering, you should
carefully read the prospectus supplement and the accompanying
prospectus, together with the information incorporated therein. These
documents contain important information that you should consider when
making your investment decision. TherapeuticsMD’s SEC filings are
available to the public from the SEC’s website at www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to these securities may also be obtained by contacting Goldman,
Sachs & Co., Prospectus Department, 200 West Street, New York, NY
10282-2198, by calling (866) 471-2526 or by emailing prospectus-ny@ny.email.gs.com;
or Cowen and Company, LLC at c/o Broadridge Financial Services, 1155
Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or
by phone (631) 274-2806 / Fax (631) 254-7140.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing products exclusively for women. With its
SYMBODA™ technology, TherapeuticsMD is developing advanced hormone
therapy pharmaceutical products to enable delivery of bio-identical
hormones through a variety of dosage forms and administration routes.
The company’s clinical development pipeline includes two phase 3
products. The company also manufactures and distributes branded and
generic prescription prenatal vitamins as well as over-the-counter
vitamins under the vitaMedMD® and BocaGreenMD® brands.

Forward Looking Statements

This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that TherapeuticsMD
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
TherapeuticsMD undertakes no duty to update or revise any such
statements, whether as a result of new information, future events or
otherwise. Forward-looking statements are not guarantees of future
performance and are subject to risks and uncertainties, many of which
are outside of TherapeuticsMD’s control. These forward-looking
statements are subject to risks and uncertainties that may cause actual
results to differ materially, including the risks and uncertainties
associated with market conditions, the satisfaction of customary closing
conditions related to the offering, risks and uncertainties associated
with TherapeuticsMD’s business and finances in general and other risks
described in the sections titled “Risk Factors” in TherapeuticsMD’s
filings with the SEC, including its most recent Annual Report on Form
10-K and other filings with the SEC.

Contacts

TherapeuticsMD, Inc.
Daniel A. Cartwright, 561-961-1900
Chief
Financial Officer
Dan.Cartwright@TherapeuticsMD.com